This April 28, 2009 photo shows Novavax, a Rockville, Maryland, company that in 2005 turned its attention to flu vaccines, is testing cell-based technologies to enable it to produce a flu vaccine in as little as three months, half as long as traditional flu vaccine makers, which use an egg-based process.
Mandatory Credit: Paul J. Richards/AFP/Getty Images
Stories this photo appears in:
FDA advisers to weigh risks and benefits of Novavax's Covid-19 vaccine
After more than a year with two types of Covid-19 vaccines in use in the United States, another will be up for consideration by the US Food and Drug Administration next week.
